Search results
Eli Lilly Surges After Weight-Loss Drug Obliterates Sales Views
Investor's Business Daily· 6 days agoIn the March quarter, Zepbound brought in $517.4 million in sales, beating forecasts for $373...
Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit despite supply issues
WSLS Newschannel 10 Roanoke· 6 days agoRapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro,...
Is Eli Lilly Stock A Buy After Weight-Loss Drug Crushes Quarterly Sales Forecasts?
Investor's Business Daily· 6 days agoIn the first quarter, sales of both rocketed higher, but only Zepbound sales topped expectations....
Eli Lilly (LLY) Q1 Earnings Top, Sales Miss, 2024 View Raised
Zacks via Yahoo Finance· 6 days agoEli Lilly (LLY) beats first-quarter estimates for earnings but misses the same for sales. It raises...
Eli Lilly's Weight-Loss Drug Still Going Strong, Boosts Annual Forecast
Benzinga via AOL· 6 days agoThe volume increase was primarily driven by growth from Mounjaro, Zepbound, Verzenio, and Jardiance,...
Unpacking the Latest Options Trading Trends in Eli Lilly and Co - Eli Lilly and Co (NYSE:LLY)
Benzinga· 4 days agoLilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology. Current ...
About 79% of the S&P 500 names beat on EPS this week - Earnings
Seeking Alpha· 10 hours agoA recap of the first quarter earnings week on Wall Street, highlighting the performances of big...
Eli Lilly and Company (NYSE:LLY) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 4 days agoEli Lilly and Company (NYSE:LLY) Q1 2024 Earnings Call Transcript April 30, 2024 Eli Lilly and...
Lilly hikes revenue forecast by $2B as GLP-1 drug sales climb
BioPharma Dive via Yahoo Finance· 6 days agoLilly noted that its so-called “incretin medicines” — a group that also includes its earlier...
Eli Lilly Shares Jump After It Signals Increase in Production of Obesity, Diabetes Drugs
The Wall Street Journal· 6 days agoSales of diabetes drugs Mounjaro and Trulicity came in lower than analysts expected, which BMO...